DaltonTx lands £4M to advance the intelligence backbone of drug discovery

UK-based technology
company DaltonTx has exited stealth and completed a £4 million seed financing
round. Backed by Redalpine, IQ Capital Partners, and Seedcamp, with additional
support from Oxford University Innovation, DaltonTx will use this funding to
redefine how technology transforms drug discovery.

Pharma has a rare chance
to make discovery faster and more effective with AI, but creating adaptive
platforms demands years of engineering and deep scientific know-how. DaltonTx
addresses this gap with a disease- and technology-agnostic platform that plugs
into pharma, biotech, and CRO workflows, giving teams immediate access to AI-enabled
discovery instead of building it in-house.

DaltonTx was founded by
Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE, bringing decades of real-world experience in drug
discovery, machine learning, and software engineering.

Built by scientists for
scientists, DaltonTx goes beyond predictive modelling to power the entire
discovery loop, from raw data and model training to molecular design,
synthesis, and decision-making. It’s not merely predictive, it’s adaptive: a
reasoning engine that learns from every scientist, model, and experiment to improve outcomes continuously.

DaltonTx’s platform is
purpose-built for both small molecules and biologics, making it well-suited to
the most complex R&D pipelines. It also enables collaborative intelligence,
allowing scientists to work with an engine that iterates and learns, combining
human insight with machine learning in real time.

As explained by Dr Garry
Pairaudeau, the company was created to change the status quo. It tackles
high-impact problems with adaptive, AI-enabled systems that slot into
scientific workflows, learn from every experiment, and equip organisations with
durable AI capability.

The
funds will be used to build adaptive, AI-enabled discovery platforms that
reshape the economics, timelines, and outcomes of R&D so breakthrough
medicines reach patients faster.